Clinical Trial Update: A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 [Phase 1, Phase 2]

View source ↗

Summary

Korro Bio has terminated the Phase 1/2a study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD), which involved single- and multiple-dose escalation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• KRRO-110

Snippet

Sponsor: Korro Bio, Inc. | Conditions: Alpha-1 Anti-trypsin Deficiency, AATD | Phase 1, Phase 2 | Status: TERMINATED